It is hard to believe that the industry could agree to what is included in the options paper - a new and complex accelerated funding pathway, which would be rarely used, in return for more power for advisory committees and decision-makers, a formal disinvestment framework, and new pricing policies.
A radical reworking of decision-making in the government's favour and it must be resisted
January 28, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 15 May
May 15, 2026 - - Podcast -
New Zealand still falling behind on access to modern medicines
May 15, 2026 - - Latest News -
AusBiotech welcomes Budget's creation of new National Resilience and Science Council
May 15, 2026 - - Latest News -
Minister fired the starting gun in March, he flung the door open in Budget week
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News
